Proven Connect Logo
Nanovery
Nanovery is developing nanorobots to diagnose the world's deadliest diseases. Collaborating with renowned academic and clinical partners, giving us access to thousands of patient samples and a proprietary dataset.
Investment Overview
Target: September 30, 2022
Minimum: 50k
Stage: Rolling Investment
Minimum: 50k

Share this

Nanovery is developing nanorobots to diagnose the world's deadliest diseases. Collaborating with renowned academic and clinical partners, giving us access to thousands of patient samples and a proprietary dataset.

Investment Details

Detecting cancer from a blood sample is still too slow

Recent advances have enabled early detection of cancers with just a blood sample, but this can still take 2 weeks. Cancer diagnoses using scans and tissue biopsy are slow, expensive and risky for patients. With the advancement of liquid biopsy, patients can be screened or diagnosed with just a blood sample, but this technique is still slow and expensive as it relies on PCR and sequencing.

We are creating a point-of-care solution that is 10× cheaper and 100× faster

Our nanorobots are added to blood samples. When they capture a cancer biomarker they light up, allowing point-of-care testing. As there is no need for high capital expenditure, our nanorobots are 10 times cheaper. The whole process is also more than 100 times faster – a matter of one or two hours rather than weeks – as there is no need for complex lab protocols which require bioinformaticians to analyse the data.

Investment Highlights
As seen in Tech Crunch
Thousands of patient samples and a proprietary dataset
A point-of-care solution that is 10 × cheaper and 100 × faster